Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK seeks to market orlistat in Europe

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline's marketing application for a 60 mg nonprescription orlistat weight loss product has been accepted for review by the European Agency for the Evaluation of Medicinal Products, the firm announces Oct. 2. GSK seeks a license to market the drug in all 27 EU member countries, though initial launch markets have not been confirmed, the firm notes. Known in the U.S. as alli, the OTC product was approved by FDA in February (1"The Tan Sheet" Feb. 12, 2007, p. 8). On sale in the U.S. since June, alli is the only FDA-approved weight loss product available without a prescription...

You may also be interested in...



Behavioral Science Banner Maps The Future Of GSK Consumer Business

Roger Scarlett-Smith, the new head of GlaxoSmithKline's North American Consumer Healthcare business, believes a nonprescription statin is probably inevitable in the U.S., and his firm still wants to be in early on that opportunity

Alli Approved OTC For Weight Loss With “Goal Oriented” Indication

FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed

Pooled Procurement Of Cancer Drugs In India: Is Pharma Game For More?

India’s National Cancer Grid pilots pooled procurement for 40 drugs including trastuzumab, imatinib, and pemetrexed, delivering median savings of over 80%. Experts discuss with Scrip the prospects of scaling the initiative and what it may mean for pharma’s margins and go-to-market strategy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel